Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Rationale for routine use of IORT for early breast cancer and data for specific indications

Dr Hans-Christian Kolberg - Marienhospital Bottrop gGmbH, Bottrop, Germany
Rationale for routine use of IORT for early breast cancer and data for specific indications ( Dr Hans-Christian Kolberg - Marienhospital Bottrop gGmbH, Bottrop, Germany )
29 Jun 2023

Chest wall perforator flaps in breast cancer surgery: An overview

Dr Sanjit Agrawal - Tata Medical Center, Kolkata, India
Chest wall perforator flaps in breast cancer surgery: An overview ( Dr Sanjit Agrawal - Tata Medical Center, Kolkata, India )
22 Jun 2023

Advancing breast cancer treatment in Uganda by improving molecular testing

Dr Jackson Orem - Uganda Cancer Institute, Kampala, Uganda
Advancing breast cancer treatment in Uganda by improving molecular testing ( Dr Jackson Orem - Uganda Cancer Institute, Kampala, Uganda )
8 Jun 2023

Somatic mutation profile of breast cancer in Uganda

Dr Manoj Menon - Fred Hutchinson Cancer Center, Seattle, USA
Somatic mutation profile of breast cancer in Uganda ( Dr Manoj Menon - Fred Hutchinson Cancer Center, Seattle, USA )
8 Jun 2023

ASCO 2023: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada
ASCO 2023: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )
6 Jun 2023

CDK4/6 inhibitors added to first line show no greater benefit when compared to their use in second line therapy in HR+, HER2- ABC

Dr Gabe Sonke - Netherlands Cancer Institute, Amsterdam, Netherlands
CDK4/6 inhibitors added to first line show no greater benefit when compared to their use in second line therapy in HR+, HER2- ABC ( Dr Gabe Sonke - Netherlands Cancer Institute, Amsterdam, Netherlands )
6 Jun 2023

Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis

Dr Chiara Molinelli - Università degli Studi di Genova, Genoa, Italy
Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis ( Dr Chiara Molinelli - Università degli Studi di Genova, Genoa, Italy )
6 Jun 2023

PHERGain trial ID's early breast cancer cases that benefit from dual HER2 blockade without chemo

Dr Javier Cortes - Vall d’Hebron University Hospital, Barcelona, Spain
PHERGain trial ID's early breast cancer cases that benefit from dual HER2 blockade without chemo ( Dr Javier Cortes - Vall d’Hebron University Hospital, Barcelona, Spain )
5 Jun 2023

ASCO 2023: Breast cancer research highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
ASCO 2023: Breast cancer research highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
5 Jun 2023

Adding ribociclib to endocrine therapy shows an improvement in invasive disease-free survival in HR+/HER2 BC patients

Prof Dennis Slamon - UCLA, Los Angeles, USA
Adding ribociclib to endocrine therapy shows an improvement in invasive disease-free survival in HR+/HER2 BC patients ( Prof Dennis Slamon - UCLA, Los Angeles, USA )
3 Jun 2023

Nine-weeks trastuzumab still effective compared with one year trastuzumab for early-stage HER2 positive breast cancer

Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy
Nine-weeks trastuzumab still effective compared with one year trastuzumab for early-stage HER2 positive breast cancer ( Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy )
3 Jun 2023

Oncologic safety of breast conservation following NACT in women with locally advanced breast cancer

Dr Sanjit Agrawal - Tata Medical Center, Kolkata, India
Oncologic safety of breast conservation following NACT in women with locally advanced breast cancer ( Dr Sanjit Agrawal - Tata Medical Center, Kolkata, India )
25 May 2023